Board summary
Key figures
37,480
Registered population
59.2% aged 18–64
18.8%
Aged 65+
ICB 14.9% · England 17.9%
21.7%
Ethnic minority (non-White)
14.7% Asian · England 9.6%
52.2%
In IMD quintile 1
ICB 40.7% · England 21.0%
~18,610
Core20 residents (est.)
Resident basis; registered basis ~19,423 · see page 3
6,198
Hypertension register
+5.08% in 3 yrs · England +5.60%
444
SMI register
12.2% of Bolton (LAD)'s
1,192
COPD register
Reviews -7.40% in 3 yrs
Forecast to 2030
6,922
Hypertension patients, 2030
+724 on today
76.7%
QRISK ≥20% on statins, 2030
+3.19pp over 3 yrs
4.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Three-year clinical trends trail England.
Of 25 measures, 22 trail England over 2023 to 2025, led by heart failure reviews (-9.5% vs +8.7%) and asthma reviews (-9.2% vs +4.4%).
Wide inter-practice phone access divergence.
Phone access spans 48.5 pp from 34.8% at The Alastair Ross Medical Practice to 83.3% at Tonge Fold Health Centre, which may reflect triage.
High current lipid therapy and respiratory reviews.
Current QRISK ≥ 20% lipid therapy reaches 69.8% (England 63.6%), alongside 81.5% COPD reviews (England 76.4%) and 70.2% asthma reviews (England 65.7%).
Population, age and ethnicity
Dual-ended age demand pairs 22.0% children with 18.8% older adults across 37,480 patients
Across member practices, the PCN registers 37,480 patients with dual-ended age demand: 22.0% (8,245) are aged 0-17 against 23.7% in Bolton, 21.8% in the ICB and 19.6% in England, while 18.8% (7,054) are aged 65+ against 14.7% in Bolton, 14.9% in the ICB and 17.9% in England. Resident Census estimates show a 21.7% ethnic minority share, including 14.7% Asian or Asian British residents against 20.1% in Bolton, 13.6% in the ICB and 9.6% in England. This structure may shape paediatric and older-adult service demand. Registered patient counts and resident Census bases differ.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Bolton (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Bolton LA) | 1,923 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.0% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.9% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Bolton LA) | 958 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Bolton LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 52.2% of patients, spanning a 56.7 pp inter-practice range
In Breightmet & Little Lever PCN, 52.2% of registered patients live in Core20 areas, exceeding Bolton (47.8%), NHS Greater Manchester Integrated Care Board (40.7%) and England (21.0%). While weighted practice rates average 51.8% (a 0.41 pp reconciliation difference), practice concentration spans 56.7 pp, from 14.3% at Little Lever Health Centre 2 to 71.0% at The Alastair Ross Medical Practice. Caseload volume highlights delivery demands: The Dunstan Partnership carries 6,182 estimated Core20 patients (61.8%), The Alastair Ross Medical Practice 5,378 (71.0%), and Tonge Fold Health Centre 4,501 (64.5%).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
444
SMI register
1.19% recorded prevalence
254
Learning disability register
0.68% recorded prevalence
13
Care homes, 446 beds
In the PCN catchment
9.8%
Provide unpaid care
Bolton (LAD), Census 2021
The PCN records 444 patients on the severe mental illness register (1.2% prevalence) and 254 on the learning disability register (0.7%), both above England (1.0% and 0.6%). The catchment also includes 13 care homes with 446 beds, although bed counts do not establish registered patient occupancy. With both registers above England benchmarks, maintaining routine physical-health checks and care-home coordination may represent key inclusion-health workloads to protect.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks reach 84.4% and BMI checks 83.2%, above England (83.4% and 82.1%). However, three-year BMI checks fell 0.7 pp against England's +5.1 pp rise, which may indicate physical monitoring slippage.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,198
Hypertension register
+5.08%
Register growth, 3 yrs
Bolton (LAD) +4.70% · England +5.60%
−4.80pp
BP control, under 80
≤140/90 · −3.44pp aged 80+
+724
More patients by 2030
Forecast 6,922 (18.32%)
Hypertension case-finding and control
Recorded hypertension prevalence is 16.6% (6,198 patients), above Bolton (14.8%), the ICB (14.4%) and England (15.2%). While 90.1% of patients had a recent blood pressure check (England 90.0%), control to target is 69.2%, having fallen 6.0 pp over three years (England +2.5 pp). For patients under 80, control is 66.1% (Bolton 67.3%, the ICB 68.6%, England 67.8%), having fallen 4.8 pp (England +2.1 pp). Falling blood pressure control despite high check coverage may reflect recall or titration slippage for patients under 80.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy coverage is 69.8%, exceeding Bolton (63.0%), the ICB (67.0%) and England (63.6%). Diabetic statin coverage also leads England, reaching 76.6% without CVD and 86.5% with CVD. Higher lipid therapy coverage than England indicates strong primary prevention reach, supporting ongoing routine review schedules.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 67,796 | £2.00 | £1.94 | £1.86 | £135,592 |
| Cardiovascular (all), 2025 | 91,791 | £4.16 | £3.15 | £3.33 | £381,851 |
In 2026, lipid-modifying drugs cost £2.00 per item across 67,796 items, above Bolton (£1.81), the ICB (£1.94) and England (£1.86), spending £9,491 more than at England's unit cost. Unit-cost differences represent a descriptive cost indicator rather than an efficiency measure, though formulary review could identify local spend drivers.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−9.21%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.39%
Asthma prevalence, PCN 3-yr % change
Recorded COPD prevalence is 3.2% (1,192 patients) and asthma prevalence is 7.4% (2,595 patients), both above England (1.9% and 6.6%). Annual reviews also exceed national levels at 81.5% for COPD (England 76.4%) and 70.2% for asthma (England 65.7%). However, both show three-year erosion: COPD reviews fell 7.4% (England +2.8%) and asthma reviews fell 9.2% (England +4.4%), leaving about 770 asthma patients unreviewed. Alongside elevated youth asthma prescribing (2,437 items per 1,000 aged 5-19 vs 1,488 in England), practices should prioritise proactive respiratory recall.
Cancer register and children's immunisation
Cancer prevalence is 3.9% (1,449 patients), in line with England (3.8%). In childhood immunisations, age-5 MMR dose 1 coverage reaches 99.1% (England 91.7%), but dose 2 drops to 91.5% (a 7.6 pp difference) and the 4-in-1 booster reaches 88.7%, both below the 95.0% target. Slower uptake of second doses and boosters leaves a vulnerable cohort before school entry, making pre-school recall the key operational opportunity.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of cancers with a known stage across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 staged cases), in line with England (55.3%) but 19.4 pp below the 75.0% national ambition by 2028. Staging was known for 70.8% of registrations (11,679 of 16,492). Closing the ICB ambition gap requires about 2,270 additional early-stage diagnoses annually. Early staging rose 3.1 pp from 52.4% in 2013. These ICB figures reflect wider system staging rather than PCN performance, while PCN cervical screening (68.6%) and breast screening (72.5%) both exceed England.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Bolton NHS Foundation Trust achieved 69.7% on the cancer 62-day referral to treatment standard, 15.3 pp below the 85.0% standard. This trailed Northern Care Alliance NHS Foundation Trust (78.6%), Manchester University NHS Foundation Trust (72.8%), NHS Greater Manchester Integrated Care Board (75.7%) and England (71.2%). However, Bolton met the 28-day faster diagnosis standard at 80.5% (standard 75.0%) and the 31-day combined treatment standard at 96.5% (standard 96.0%). For diagnostics in Jul 2026, 25.3% waited 6+ weeks for cystoscopy at Bolton (England 24.4%), while 6+ week MRI waits were 2.0% (England 21.4%).
| Pathways within standard (%) | Bolton | Northern Care Alliance | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.48 | 75.20 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.50 | 94.54 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 69.66 | 78.65 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Bolton | Northern Care Alliance | Manchester | England |
|---|---|---|---|---|
| MRI | 2.05 | 5.09 | 11.68 | 21.40 |
| CT | 19.40 | 4.10 | 14.66 | 9.92 |
| Echocardiography | 3.48 | 31.48 | 4.91 | 28.48 |
| Colonoscopy | 1.33 | 40.04 | 4.51 | 30.83 |
| Gastroscopy | 2.06 | 36.48 | 29.35 | 29.02 |
| All 15 DM01 tests | 15.78 | 15.71 | 8.98 | 23.14 |
| Community services activity | Bolton residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 49,315 | 573,310 |
| Referrals | 4,075 | 94,470 |
| Patients with a contact | 17,765 | 183,535 |
Community services (residents of Bolton), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 51.6% of community service contacts among Bolton borough residents (25,460 of 49,315 total contacts). This highlights that community services predominantly manage older-age care across the local authority, although activity is published at borough resident level rather than by primary care network.
Practice variation and patient experience
Patient phone access varies by 48.5 percentage points across practices
Across 2025/26, QOF overall achievement ranged from 85.7% at Little Lever Health Centre 1 to 96.8% at Spring View Medical Centre (England 92.5%). Vaccination and immunisation achievement spanned 46.7 pp, trailing England (55.2%) down to 24.8% at The Alastair Ross Medical Practice.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Tonge Fold | 97 | 64.5 | 83.3% | 84.5% | 88.5% |
| Little Lever 1 | 96 | 41.8 | 59.6% | 75.7% | 84.7% |
| Dunstan | 116 | 61.8 | 51.6% | 77.8% | 82.9% |
| Spring View | 102 | 18.1 | 54.4% | 65.6% | 78.4% |
| Little Lever 2 | 102 | 14.3 | 75.1% | 77.6% | 73.6% |
| Alastair Ross | 84 | 71.0 | 34.8% | 75.7% | 67.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Three-year change trails England across 22 of 25 measures despite high current achievement
Across 22 of 25 compared measures, three-year change trails England over 2023 to 2025. Heart failure reviews fell 9.5% (England +8.7%), asthma reviews fell 9.2% (England +4.4%), hypertension treated to target fell 8.0% (England +3.6%), and COPD reviews fell 7.4% (England +2.8%). Current achievement remains above England for asthma reviews (70.2% vs 65.7%), COPD reviews (81.5% vs 76.4%), and diabetes HbA1c control without frailty (58.9% vs 57.4%) and with frailty (84.0% vs 81.9%). This erosion could reflect recall slippage testable by register audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
Hypertension treated to target
COPD reviews
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Bolton (LAD) | Asset | PCN | Bolton (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 13 (446 beds) | n/a | Schools (catchment) | 50 | n/a |
| Children's centres | 4 | 18 | Places of worship | 31 | 144 |
| Libraries | 1 | 7 | Primary schools (LA maintained) | 9 | 61 |
| Primary academies | 11 | 32 | Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Respiratory and heart failure recall audit
Asthma reviews (70.2%, 2,595 register) fell 9.2% over 2023 to 2025 (England +4.4%), leaving 772 (about 770) unreviewed; COPD reviews fell 7.4% and heart failure 9.5%. For discussion: run a shared annual review recall across the 2,595 asthma, 1,192 COPD and 331 heart failure registers, starting in Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension titration and under-80 recall
Across 6,198 hypertension patients (16.6%), target control is 69.2% (England 70.3%), falling 8.0% or 6.0 pp (England +3.6%, +2.5 pp); under-80 control (66.1%) fell 4.8 pp. For discussion: deploy clinical pharmacists to review and titrate patients on the 6,198 hypertension register above target, focusing on patients under 80. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Pre-school booster and phone access review
Age-5 MMR drops 7.6 pp from dose 1 (99.1%) to dose 2 (91.5%), with 4-in-1 at 88.7% (below 95.0% by 6.3 pp); phone access spans 48.5 pp (34.8% to 83.3%). Low cost, quick to run.
Evidence base: the share of patients in the most deprived quintile is the Core20 targeting measure used to weight inequalities funding, outreach and prevention capacity, and the gradient every clinical indicator should be read against.
Policy anchor: Core20PLUS5 (Core20 = the most deprived 20% by IMD); 10 Year Health Plan, with widening inequalities the equity test of reform.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Differentiated Core20 resource allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check audit (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Blood pressure titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Telephone access and triage review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Respiratory and heart failure recall audit (p12) | Asthma register · COPD register · Heart failure register | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension titration and under-80 recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Pre-school booster and phone access review (p12) | Core20 cohort (IMD quintile 1) · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | Core20PLUS5 · 10YHP equity test · 10YHP sickness to prevention · 95% target | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
